SYRE News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

SY

Mkt Cap

$7.47B

Volume

881.95K

Next Earnings

November 3rd

Loading chart

SY

SYRESpyre Therapeutics, Inc. Common Stock

SYRE

Pay with—

Available Balance0.00

SY

Mkt Cap

$7.47B

Volume

881.95K

Next Earnings

November 3rd

Chart Financials Earnings News About Insider Filings

Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common StockSpyre Therapeutics priced its underwritten public offering at $85 per share, raising approximately $350 million in gross proceeds. The company plans to use the funds to advance its immunology programs in gastroenterology, rheumatology, and dermatology, including Phase 3 readiness and development of SPY072 for hidradenitis suppurativa. The offering is expected to close on October 7, 2026.GlobeNewswire Inc. · Oct 6, 2026

Spyre Therapeutics (SYRE) Down 16.6% Since Last Earnings Report: Can It Rebound?Spyre Therapeutics shares have declined 16.6% since its Q2 2026 earnings report, underperforming the S&P 500. The company reported a narrower-than-expected loss of 36 cents per share and benefited from a $40 million gain on asset sales, though R&D expenses surged 63.2% year-over-year. With $1.15 billion in cash expected to fund operations into late 2029, analyst estimates have shifted downward by 10.44%, and the stock holds a Zacks Rank #3 (Hold) rating.Zacks Investment Research · Sep 3, 2026

Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common StockSpyre Therapeutics priced an underwritten public offering of 6.5 million shares at $62.00 per share, generating approximately $403 million in gross proceeds. The offering is expected to close on April 16, 2026. Joint book-running managers include Jefferies LLC, Goldman Sachs & Co. LLC, Evercore ISI, and Guggenheim Securities, LLC.GlobeNewswire Inc. · Apr 15, 2026

Spyre Therapeutics Announces Proposed Public Offering of its Common StockSpyre Therapeutics, a clinical-stage biotechnology company focused on inflammatory bowel disease treatments, announced a proposed underwritten public offering of $300 million in common stock, with an additional $45 million option for underwriters. The offering is subject to market conditions and regulatory approval, with Jefferies LLC, Goldman Sachs & Co. LLC, Evercore ISI, and Guggenheim Securities serving as joint book-running managers.Benzinga · Apr 13, 2026

Spyre Therapeutics Announces Proposed Public Offering of its Common StockSpyre Therapeutics, a clinical-stage biotechnology company focused on IBD and immune-mediated diseases, announced a $300 million underwritten public offering of common stock with a potential additional $45 million option for underwriters. The offering is led by Jefferies LLC, Goldman Sachs & Co. LLC, Evercore ISI, and Guggenheim Securities as joint book-running managers.GlobeNewswire Inc. · Apr 13, 2026

Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis PatientsSpyre Therapeutics announced positive Phase 2 SKYLINE trial results for SPY001, an extended half-life anti-α4β7 antibody for moderate-to-severe ulcerative colitis. SPY001 met its primary endpoint with a statistically significant 9.2-point reduction in Robart's Histopathology Index score (p<0.0001) at Week 12, with secondary endpoints showing 40% clinical remission and 51% endoscopic improvement rates. The drug demonstrated a favorable safety profile consistent with its class. Part A enrollment has closed and Part B is now enrolling monotherapy and combination cohorts.GlobeNewswire Inc. · Apr 13, 2026

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for FoolsVR Adviser, LLC increased its position in Spyre Therapeutics by 1 million shares (estimated $25.78 million) in Q4, bringing total holdings to 3.68 million shares valued at $120.74 million (5.96% of AUM). Spyre Therapeutics, a preclinical-stage biotech company developing antibody therapies for inflammatory bowel disease, has seen its stock surge 132.1% over the past year. The article cautions that while VR Adviser is specialist biotech fund with deep expertise, Spyre's preclinical status and binary pipeline risk make it unsuitable for most individual investors.The Motley Fool · Mar 19, 2026

Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 MillionCommodore Capital increased its stake in Spyre Therapeutics by 400,161 shares ($10.46 million) in Q4, bringing its total position to $78.24 million (5.21% of AUM). SYRE stock has surged 63% over the past year, significantly outperforming the S&P 500's 13% gain. The preclinical biotech company, focused on inflammatory bowel disease treatments, has a strong balance sheet with $757 million in cash and expects runway into H2 2028, with six Phase 2 readouts expected in 2026.The Motley Fool · Feb 23, 2026

Spyre Therapeutics Announces Grants of Inducement AwardsSpyre Therapeutics announced the appointment of Kate Chevlen as Chief Commercial Officer, granting her 108,155 stock options at an exercise price of $34.09 per share as an inducement award. The options vest over four years with a 10-year term.GlobeNewswire Inc. · Jan 23, 2026

Spyre Therapeutics' CEO Sells 15,000 SharesSpyre Therapeutics CEO Cameron Turtle sold 15,000 shares for approximately $460,000 on January 2, 2026, representing 2.2% of his direct holdings. The sale was conducted under a prearranged 10b5-1 trading plan, which is a standard practice for insiders to avoid appearance of impropriety. After the transaction, Turtle retained approximately 671,907 shares valued at $20.5 million. The analyst notes the sale is not concerning given the scheduled nature of the plan.The Motley Fool · Jan 11, 2026

to start trading

SY

SYRESpyre Therapeutics, Inc. Common Stock

SYRE

Pay with—

Available Balance0.00

Your PositionYou don't own any SYRE yet.

Related Tickers

Earnings